SNS-301 Monotherapy in High Risk MDS and CMML

NCT ID: NCT04217720

Last Updated: 2021-08-12

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-04-01
• Study Completion Date: 2023-01-01

Brief Summary

To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 in patients with ASPH+ high risk MDS and CMML.

Detailed Description

This phase 2, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of intradermally-delivered SNS-301 delivered using the 3M® hollow microstructured transdermal system (hMTS) device in patients with ASPH+ high risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial population consists of high risk ≥ Intermediate Risk-3 (IR-3) MDS and CMML-2.

Conditions

Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia (CMML)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SNS-301

SNS-301

Group Type: EXPERIMENTAL

SNS-301

Intervention Type: DRUG

SNS-301 (1x 1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.

Interventions

SNS-301

SNS-301 (1x 1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent.

2. Be 18 years of age or older.

3. Confirmed diagnosis of MDS or CMML.

4. Assessment of high-risk-MDS/CMML status defined as follows:

1. MDS: IPSS-R criteria for categorization ≥ Intermediate Risk-3

2. CMML: WHO criteria for CMML-2 (peripheral blasts of 5% to 19%, and 10% to 19% bone marrow blasts and/or presence of Auer rods).

5. Be willing to provide a fresh bone marrow aspirate sample at pre-treatment and demonstrate ASPH expression by flow cytometry.

6. Patient who has relapsed or is refractory / intolerant of hypomethylating agents (HMAs) or not responding to 4 treatment cycles of decitabine or 6 treatment cycles of azacytidine or progressing at any point after initiation of an HMA.

7. Patient refuses or is not considered a candidate for intensive induction chemotherapy using consensus criteria for defining such patients.

8. Patients with CMML must have been treated with at least 1 prior therapy (hydroxyurea or an HMA).

9. Eastern Cooperative Oncology Group (ECOG) Performance Scale 0-1.

10. Demonstrate adequate organ function: renal, hepatic, coagulation parameters.

11. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment. For male patients: Agree that during the period specified above, men will not father a child. Male patients must remain abstinent, must be surgically sterile during the treatment period and for at least 180 days after the last dose of study treatment.

Exclusion Criteria

1. Any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy or radiation therapy within 2 weeks prior to trial Day 0.

2. Participated on a clinical trial of an investigational agent and/or investigational device within 28 days prior to Day 0.

3. Malignancies other than indications open for enrollment within 3 years prior to Day 0.

4. Diagnosis of a core binding factor leukemia (t(8;21), t(16;16); or inv(16)) or diagnosis of acute promyelocytic leukemia (t(15;17)).

5. Active or history of autoimmune disease or immune deficiency.

6. History of HIV. HIV antibody testing recommended per investigator's clinical suspicion.

7. Active hepatitis B (hepatitis B surface antigen reactive) or active hepatitis C (HCV qualitative RNA detected); testing recommended per investigator's clinical suspicion.

8. Severe infections within 4 weeks prior to enrollment.

9. Received therapeutic oral or IV antibiotics within 2 weeks prior to Day 0.

10. History or current evidence of any condition, therapy or laboratory abnormality that in the opinion of the treating investigator might confound the results of the trial.

11. Known previous or ongoing, active psychiatric or substance abuse disorders that would interfere with the requirements of the trial.

12. Treatment with systemic immunomodulating agents (including but not limited to IFNs, IL-2) within 6 weeks or five half-lives of the drug, whichever is shorter, prior to first dose.

13. Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sensei Biotherapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ildiko Csiki, MD, PhD

Role: STUDY_DIRECTOR

Sensei Biotherapeutics

Other Identifiers

SNS-301-2-1

Identifier Type: -

Identifier Source: org_study_id